Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MSI-195 vs Commercial SAM-e in Healthy Volunteers
NCT04623034Phase 1Completed
- Sponsor
- MSI Methylation Sciences
- Start
- Apr 2013
- Primary completion
- Jun 2013
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of S-adenosylmethionine in major depressive disorder (MDD) (6 arms), sponsored by MSI Methylation Sciences. Primary endpoints: Incidence and severity of treatment-related adverse events, Systemic plasma concentration of ademetionine and 4 more. Started Apr 2013; status: completed.
02
Drugs
S-adenosylmethionine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04623034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623034.